The p53 gene in pediatric therapy-related leukemia and myelodysplasia

Blood

Volumn 87, Issue 10, 1996, Pages 4376-4381

  Felix, Carolyn A ^a   Hosler, Matthew R ^b   Provisor, Deborah ^b   Salhany, Kevin ^b   Sexsmith, Elizabeth A ^b   Slater, Diana J ^b   Cheung, Nai Kong V ^b   Winick, Naomi J ^b   Strauss, Eric A ^b   Heyn, Ruth ^b   Lange, Beverly J ^b   Malkin, David ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; PROTEIN P53;

ARTICLE; BASE PAIRING; CELL DEATH; CHROMOSOME 17; CODON; ENZYME INHIBITION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; LEUKEMIA; MYELODYSPLASTIC SYNDROME; OPEN READING FRAME; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 9344265760     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4376.bloodjournal87104376     Document Type: Article

References (66)

1. McBride OW, Merry D, Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83:130, 1986
2. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 tumour antigen to band 17p13. Nature 320:84, 1986
3. Finlay CA, Hinds PW, Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57:1083, 1989
4. Lamb P, Crawford L: Characterization of the human p53 gene. Mol Cell Biol 6: 1379, 1986
5. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE: Growth arrest induced by wild-type p53 blocks cells prior to or near the restriction point in late G1-phase. Proc Natl Acad Sci USA 89:9210, 1992
6. Mercer WE: Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Express 2:251, 1992
7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304, 1991
8. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
9. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849, 1993
10. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689, 1984
11. Kuerbitz SJ, Pkunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491, 1992
12. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
13. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937, 1992
14. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923, 1992
15. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
16. El-Deiry W, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1:45, 1992
17. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman K, Mercer W, Kastan M, Kohn K, Elledge S, Kinzler K, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169, 1994
18. Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W, Plunkett B, Vogelstein B, Fornace A: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587, 1992
19. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF: Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:13560, 1984
20. Wang JC, Caron PR, Kim RA: The role of DNA topoisomerases in recombination and genome stability: A double-edged sword? Cell 62:403, 1990
21. Long BH, Musial ST, Brattain MG: Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45:3106, 1985
22. Epstein RJ: Topoisomerases in human disease. Lancet 1:521, 1988
23. Osheroff N, Zechiedrich EL, Gale KC: Catalytic function of DNA topoisomerase II. Bioessays 13:269, 1991
24. Osheroff N, Robinson MJ, Zechiedrich EL: Mechanism of the topoisomerase II - mediated DNA cleavage-religation reaction: Inhibition of DNA religation by antineoplastic drugs, in Potmesil M, Kohn K (ed): DNA Topoisomerases in Cancer. New York, NY, Oxford University Press, 1991, p 230
25. Capranico G, Zunino F: DNA topoisomerase II - trapping antitumor drugs. Eur J Cancer 28A:2055, 1992
26. Pommier Y, Bertrand R: The mechanisms of formation of chromosomal aberrations: Role of eukaryotic topoisomerases, in Kirsch IR (ed): The Causes and Consequences of Chromosomal Aberrations. Boca Raton, FL, CRC, 1993, p 277
27. Corbett A, Osheroff N: When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6:585, 1993
28. Bertrand R, Kerrigan D, Sarang M, Pommier Y: Cell death induced by topoisomerase inhibitors: Role of calcium in mammalian cells. Biochem Pharmacol 42:77, 1991
29. Malkin D: p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta 1198:197, 1994
30. Li FP, Fraumeni JF: Rhabdomyosarcoma in children. J Natl Cancer Inst 43:1365, 1969
31. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. Ann Intern Med 71:747, 1969
32. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358, 1988
33. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T, Minna JD: Hereditary and acquired p53 mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89:640, 1992
34. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila I, Mulshine JS, Minna JD, Gazdar AF: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171, 1992
35. Strauss E, Hosler M, Herzog P, Salhany K, Louie R, Felix C: Complex replication error causes p53 mutation in a Li-Fraumeni family. Cancer Res 55:3237, 1995
36. Felix C, Hosler M, Winick N, Masterson M, Wilson A, Lange B: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85:3250, 1995
37. Heyn R, Khan F, Ensign LG, Donaldson SS, Ruymann F, Smith MA, Vietti T, Maurer HM: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: An interim report. Med Pediatr Oncol 23:99, 1994
38. Felix C, Brown D, Mitsudomi T, Ikagaki N, Wong A, Wasserman R, Womer R, Biegel J: Polymorphism at codon 36 of the p53 gene. Oncogene 9:327, 1994
39. Carbone D, Chiba I, Mitsudomi T: Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691, 1991
40. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen A-L, Fodstad O: p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468, 1993
41. Birch JM, Hartley AM, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Michell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298, 1994
42. Meadows AT. Risk factors for second malignant neoplasms: Report from the Late Effects Study Group. Bull Cancer 75:125, 1988
43. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, Sather HN, Hammond GD: Second neoplasms after acute lymphoblastic leukemia in children. N Engl J Med 325:1330, 1991
44. Hawkins MM, Kinnier-Wilson M, Stovall MA, Marsden HB, Potok MHN, Kingston JE, Chessells JM: Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 304:951, 1992
45. Fenaux P, Joneaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
46. Malkin D, Li FP, Strong LG, Fraumeni JJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233, 1990
47. Malkin D: p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 66:83, 1993
48. Addison C, Jenkins JR, Sturzbecher HW: The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 5:423, 1990
49. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945, 1990
50. Stephen CW, Lane DP: Mutant conformation of p53: Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225:577, 1992
51. Sturzbecher H-W, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR: A C-terminal α helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513, 1992
52. Zakut-Houri R, Bienz-Tadmaor B, Givol D, Oren M: Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J 4:1251, 1985
53. Law JC, Strong LC, Chidambaram A, Ferrell RE: A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 51:6385, 1991
54. Brugieres L, Gardes M, Moutou C, Chompret A, Meresse V, Martin A, Poisson N, Flamant F, Bonaiti-Pellie C, Lemele J, Feunten J: Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res 53:452, 1993
55. Slingerland J, Minden M, Benchimol S: Mutations of the p53 gene in human acute myelogenous leukemia. Blood 77:1500, 1991
56. Mazoyer S, Lalle P, Moyret LC, Marcais C, Schraub S, Frappaz D, Sobol H, Ozturk M: Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 9:1237, 1994
57. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa HK, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J: Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 84:703, 1992
58. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum PR, Yandell DW: Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326:1301, 1992
59. Frebourg T, Barbier N, Yan Y-X, Garber JE, Dreyfus M, Fraumeni JF, Li FP, Friend SH: Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56:608, 1995
60. Vogan K, Bernstein M, Leclerc L-M, Brisson L, Brossard J, Brodeur G, Pelletier J, Gros P: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 53:5269, 1993
61. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855, 1994
62. Felix CA, D'Amico D, Mitsudomi T, Nau MM, Li FP, Fraumeni JFJ, Cole DE, McCalla J, Reaman GH, Whang-Peng J, Knutsen T, Minna JD, Poplack DG: Absence of hereditary p53 mutations in ten familial leukemia pedigrees. J Clin Invest 90:653, 1992
63. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa K, Takaku F: Mutations of the p53 gene in lymphoid leukemia. Blood 77:1153, 1991
64. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T, Hayashi Y: Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 85:2546, 1995
65. Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD, Nachman J, Bostrom B, Baum ES, Suarez CR, Shah NR, Morgan E, Mauer HS, McKenzie SE, Larson RA, Le Beau MM: Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 78:2982, 1991
66. Winick N, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209, 1993